黄素作为治疗神经退行性疾病的潜在治疗剂
Valeria Perales-Salinas1, Sushmitha S Purushotham1, Yossi Buskila2
1School of Medicine, Western Sydney University, Campbelltown, NSW, 2560, Australia.
Neurochemistry international
|June 9, 2024
概括
神经炎症驱动神经退行性疾病. 这篇评论探讨了黄素.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 神经退行性疾病涉及渐进的神经元损失和严重的全球健康负担.
- 神经炎症是常见的标志,影响疾病的发病和进展.
- 目前对潜在的病理机制的理解仍然不完整.
研究的目的:
- 探索神经退行性疾病中的神经炎症途径.
- 评估黄素作为治疗剂的潜力.
- 检查黄素在神经退行治疗中的生物可用性,益处和挑战.
主要方法:
- 对黄素的临床前和临床研究的综述.
- 对黄素的抗氧化和抗炎性质的分析.
- 检查黄素在衰老和神经退行症中的作用.
主要成果:
- 黄素表现出抗氧化和抗炎性质.
- 临床前和临床数据表明治疗潜力.
- 黄素的生物可用性和BBB完整性需要进一步研究.
结论:
- 黄素对治疗神经退行性疾病充满希望.
- 需要进一步的研究来澄清黄素的作用机制,特别是关于大脑生理学和BBB完整性的研究.
- 阐明黄素的作用可能导致新的中枢神经系统治疗点.
相关概念视频
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
Parkinson's Disease: Overview
527
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
527
Parkinson's Disease: Treatment
257
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
257
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
120
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
120
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462


